KRAS and non-small cell lung carcinoma: We also found immune checkpoint inhibitors appear to be more effective in NSCLC patients having KRAS mutation (the OS of HR, 0.61; 95% CI, 0.39–0.94) compared with chemotherapy and no difference in NSCLC patients having KRAS wild-type (the OS of HR, 0.89; 95% CI, 0.68–1.17).